RDE Treatment Prevents Non-Specific Detection of SARS-CoV-2- and Influenza-Specific IgG Antibodies in Heat-Inactivated Serum Samples

Assessing the levels of serum IgG antibodies is widely used to measure immunity to influenza and the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after natural infection or vaccination with specific vaccines, as well as to study immune responses to these viruses in animal models. For safety reasons, sometimes serum specimens collected from infected individuals are subjected to heat inactivation at 56 °C to reduce the risk of infecting personnel during serological studies. However, this procedure may affect the level of virus-specific antibodies, making the results of antibody immunoassays uninterpretable. Here, we evaluated the effect of the heat inactivation of human, ferret and hamster serum samples on the binding of IgG antibodies to the influenza and SARS-CoV-2 antigens. For this, serum samples of naive and immune hosts were analyzed in three variants: (i) untreated sera, (ii) heated at 56 °C for 1 h, and (iii) treated with receptor-destroying enzyme (RDE). The samples were studied through an in-house enzyme-linked immunosorbent assay (ELISA) using whole influenza virus or recombinant proteins corresponding to nucleocapsid (N) protein and the receptor-binding domain of SARS-CoV-2 Spike (RBD) as antigens. We demonstrated that the heat inactivation of the naive serum samples of various hosts can lead to false-positive results, while RDE treatment abolished the effect of the non-specific binding of IgG antibodies to the viral antigens. Furthermore, RDE also significantly decreased the level of virus-specific IgG antibodies in SARS-CoV-2 and influenza-immune sera of humans and animals, although it is unknown whether it actually removes true virus-specific IgG antibodies or only non-specifically binding artifacts. Nevertheless, we suggest that the RDE treatment of human and animal sera may be useful in preventing false-positive results in various immunoassays, while also neutralizing infectious virus, since the standard protocol for the use of RDE also includes heating the sample at 56 °C.

[1]  L. Rudenko,et al.  Optimization of purification conditions and study of antigenic properties of recombinant nucleocapsid protein of different SARS-CoV-2 strains , 2022, Medical academic journal.

[2]  L. Rudenko,et al.  Assessment of cell-mediated immune responses to SARS-CoV-2 in Syrian hamsters , 2022, Medical academic journal.

[3]  Jue Liu,et al.  Effect of COVID-19 Vaccines on Reducing the Risk of Long COVID in the Real World: A Systematic Review and Meta-Analysis , 2022, International journal of environmental research and public health.

[4]  Zhiyuan Li,et al.  Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern in real-world: a literature review and meta-analysis , 2022, Emerging microbes & infections.

[5]  Irina Isakova-Sivak,et al.  Cross-Reactivity of SARS-CoV-2 Nucleocapsid-Binding Antibodies and Its Implication for COVID-19 Serology Tests , 2022, Viruses.

[6]  Wei Dong,et al.  Massive‐scale genomic analysis reveals SARS‐CoV‐2 mutation characteristics and evolutionary trends , 2022, mLife.

[7]  H. Hou,et al.  Comparison of the Performance of 24 Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Assays in the Diagnosis of Coronavirus Disease 2019 Patients , 2022, Frontiers in Microbiology.

[8]  Irina Isakova-Sivak,et al.  Development of a T Cell-Based COVID-19 Vaccine Using a Live Attenuated Influenza Vaccine Viral Vector , 2022, Vaccines.

[9]  Y. Bi,et al.  Relatively rapid evolution rates of SARS-CoV-2 spike gene at the primary stage of massive vaccination , 2022, Biosafety and Health.

[10]  A. Sette,et al.  Immunological memory to SARS‐CoV‐2 infection and COVID‐19 vaccines , 2022, Immunological reviews.

[11]  Irina Isakova-Sivak,et al.  Dysregulated Immune Responses in SARS-CoV-2-Infected Patients: A Comprehensive Overview , 2022, Viruses.

[12]  S. Lowther,et al.  Characterisation and natural progression of SARS-CoV-2 infection in ferrets , 2022, Scientific Reports.

[13]  D. Altmann,et al.  COVID-19 vaccination: The road ahead , 2022, Science.

[14]  M. Rezaei-Tavirani,et al.  Current advances and challenges in COVID-19 vaccine development: from conventional vaccines to next-generation vaccine platforms , 2022, Molecular Biology Reports.

[15]  P. Moss The T cell immune response against SARS-CoV-2 , 2022, Nature Immunology.

[16]  D. Goedhals,et al.  A systematic review and meta-analysis of the sensitivity of antibody tests for the laboratory confirmation of COVID-19 , 2021, Future virology.

[17]  D. Wang,et al.  Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice , 2021, Military Medical Research.

[18]  Yingying Song,et al.  Animal Models for COVID-19: Hamsters, Mouse, Ferret, Mink, Tree Shrew, and Non-human Primates , 2021, Frontiers in Microbiology.

[19]  G. B. Karlsson Hedestam,et al.  Immunity to SARS‐CoV‐2 induced by infection or vaccination , 2021, Journal of internal medicine.

[20]  Bofeng Li,et al.  Evaluation and Comparison of Serological Methods for COVID-19 Diagnosis , 2021, Frontiers in Molecular Biosciences.

[21]  L. Rudenko,et al.  Universal Live-Attenuated Influenza Vaccine Candidates Expressing Multiple M2e Epitopes Protect Ferrets against a High-Dose Heterologous Virus Challenge , 2021, Viruses.

[22]  Z. Rostami,et al.  A comparative review of immunoassays for COVID-19 detection , 2021, Expert review of clinical immunology.

[23]  M. Yousef,et al.  Super-rapid race for saving lives by developing COVID-19 vaccines , 2021, J. Integr. Bioinform..

[24]  J. Berzofsky,et al.  Potential SARS-CoV-2 Immune Correlates of Protection in Infection and Vaccine Immunization , 2021, Pathogens.

[25]  W. Burgers,et al.  SARS-CoV-2 evolution and vaccines: cause for concern? , 2021, The Lancet Respiratory Medicine.

[26]  S. Witkin,et al.  Nucleoprotein-based ELISA for detection of SARS-COV-2 IgG antibodies: Could an old assay be suitable for serodiagnosis of the new coronavirus? , 2021, Journal of Virological Methods.

[27]  I. Brown,et al.  Intranasal Infection of Ferrets with SARS-CoV-2 as a Model for Asymptomatic Human Infection , 2021, Viruses.

[28]  B. Clotet,et al.  Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity , 2020, Biochemical and Biophysical Research Communications.

[29]  Zhènglì Shí,et al.  Characteristics of SARS-CoV-2 and COVID-19 , 2020, Nature Reviews Microbiology.

[30]  M. Spraul,et al.  Quantitative In-Vitro Diagnostic NMR Spectroscopy for Lipoprotein and Metabolite Measurements in Plasma and Serum: Recommendations for Analytical Artifact Minimization with Special Reference to COVID-19/SARS-CoV-2 Samples , 2020, Journal of proteome research.

[31]  X. de Lamballerie,et al.  Heat Inactivation of Different Types of SARS-CoV-2 Samples: What Protocols for Biosafety, Molecular Detection and Serological Diagnostics? , 2020, Viruses.

[32]  Taixue An,et al.  Impact of heat-inactivation on the detection of SARS-CoV-2 IgM and IgG antibody by ELISA , 2020, Clinica Chimica Acta.

[33]  G. Alter,et al.  Dissecting antibody-mediated protection against SARS-CoV-2 , 2020, Nature Reviews Immunology.

[34]  Yongyu Rui,et al.  Heat inactivation of serum interferes with the immunoanalysis of antibodies to SARS-CoV-2 , 2020, medRxiv.

[35]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[36]  H. Turner,et al.  Antibody-dependent enhancement of influenza disease promoted by increase in hemagglutinin stem flexibility and virus fusion kinetics , 2019, Proceedings of the National Academy of Sciences.

[37]  L. Rudenko,et al.  Two Live Attenuated Vaccines against Recent Low–and Highly Pathogenic H7N9 Influenza Viruses Are Safe and Immunogenic in Ferrets , 2018, Vaccines.

[38]  T. Noda,et al.  Syrian Hamster as an Animal Model for the Study of Human Influenza Virus Infection , 2017, Journal of Virology.

[39]  J. Futami,et al.  Evaluation of irreversible protein thermal inactivation caused by breakage of disulphide bonds using methanethiosulphonate , 2017, Scientific Reports.

[40]  M. Koopmans,et al.  ViroSpot microneutralization assay for antigenic characterization of human influenza viruses. , 2017, Vaccine.

[41]  Shibo Jiang,et al.  Vaccines for the prevention against the threat of MERS-CoV , 2016, Expert review of vaccines.

[42]  M. Stukova,et al.  Assessment of immune responses to H5N1 inactivated influenza vaccine among individuals previously primed with H5N2 live attenuated influenza vaccine , 2015, Human vaccines & immunotherapeutics.

[43]  M. Stukova,et al.  Clinical testing of pre-pandemic live attenuated A/H5N2 influenza candidate vaccine in adult volunteers: results from a placebo-controlled, randomized double-blind phase I study. , 2015, Vaccine.

[44]  Fu-Tong Liu,et al.  Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins , 2014, Biochemical and Biophysical Research Communications.

[45]  A. Vincent,et al.  Vaccine-Induced Anti-HA2 Antibodies Promote Virus Fusion and Enhance Influenza Virus Respiratory Disease , 2013, Science Translational Medicine.

[46]  V. Nerurkar,et al.  Effect of Serum Heat-Inactivation and Dilution on Detection of Anti-WNV Antibodies in Mice by West Nile Virus E-protein Microsphere Immunoassay , 2012, PloS one.

[47]  V. Huber,et al.  Contribution of murine innate serum inhibitors toward interference within influenza virus immune assays , 2011, Influenza and other respiratory viruses.

[48]  K. Jansen,et al.  Optimization and Validation of a Multiplexed Luminex Assay To Quantify Antibodies to Neutralizing Epitopes on Human Papillomaviruses 6, 11, 16, and 18 , 2005, Clinical Diagnostic Laboratory Immunology.

[49]  John A. Maher,et al.  The Ferret: An Animal Model to Study Influenza Virus , 2004, Lab Animal.

[50]  M. Muratsugu Mechanism of aggregates generated by heating human serum. , 1996, Biological & pharmaceutical bulletin.

[51]  Sera,et al.  Distinct glycoprotein inhibitors of influenza A virus in different animal sera , 1991, Journal of virology.

[52]  D. Jungkind,et al.  Effect of using heat-inactivated serum with the Abbott human T-cell lymphotropic virus type III antibody test , 1986, Journal of clinical microbiology.

[53]  I. D. Wilson,et al.  The effect of heat inactivation of serum on aggregation of immunoglobulins. , 1979, Immunology.